Baou Katerina, Katsi Vasiliki, Makris Thomas, Tousoulis Dimitris
First Department of Pulmonary Medicine, Sismanoglio Hospital, Sismanogliou 1, Marousi, Greece.
First Department of Cardiology, Hippokration Hospital, University of Athens, Vasilissis Sofias 114, Athens, Greece.
Curr Hypertens Rev. 2021;17(3):196-206. doi: 10.2174/1573402116999201209203250.
Approximately half a century has passed since the discovery of beta-blockers. Then, their prime therapeutic purpose was to treat angina and cardiac arrhythmias; nowadays, beta-blockers' usage and effectiveness are extended to treat other cardiovascular diseases, such as hypertension, congestive heart failure, and coronary artery disease. Safety concerns were raised about beta- blockers and their use for chronic obstructive pulmonary disease (COPD) patients with concurrent cardiovascular disease. After thorough research of the literature, this review summarizes the evidence proving that beta-blockers not only might be well tolerated in COPD patients, but they might also have a beneficial effect in this group of patients.
自β受体阻滞剂被发现以来，大约半个世纪已经过去了。当时，它们的主要治疗目的是治疗心绞痛和心律失常；如今，β受体阻滞剂的用途和有效性已扩展到治疗其他心血管疾病，如高血压、充血性心力衰竭和冠状动脉疾病。人们对β受体阻滞剂及其在并发心血管疾病的慢性阻塞性肺疾病（COPD）患者中的使用提出了安全担忧。在对文献进行全面研究后，本综述总结了证据，证明β受体阻滞剂不仅可能在COPD患者中具有良好的耐受性，而且可能对这组患者产生有益影响。
